FRANKLIN, Tenn.--(BUSINESS WIRE)--July 11, 2006--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI - News) announced today that the Company has successfully completed enrollment in its Canadian pilot clinical study with its lead orthopedic product candidate GEM OS1 Bone Graft. As a result of the preliminary data obtained, the Company has received authorization from the Canadian government to expand the study from the original 20 patients up to 60 patients. Subject to the results of the expanded study, the Company intends to file for Canadian product registration for orthopedic indications in 2007.
